sapanisertib
sapanisertib: developed by 1 company · 4 clinical trials tracked.
sapanisertib evidence translation
What we can confirm
4 tracked trials
What it means
What to watch
Prepared research question
How could sapanisertib → CALA affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 2 study sponsors
Related indications
Development Pipeline (2)
| Company | Phase |
|---|---|
| Calithera Biosciences, Inc. (CALA) Squamous non-small cell lung cancer (sqNSCLC) harboring NRF2… | Phase 2 |
| Calithera Biosciences, Inc. (CALA) Oncology - being evaluated in NRF2-mutated sqNSCLC | Phase 2 |
Clinical Trials (4)
Open-Label Umbrella Study to Evaluate Safety and Efficacy of Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced or Metastatic Breast Cancer
Primary endpoint: Safety and tolerability of drugs by assessment of adverse events (AEs) / serious adverse events (SAEs)
A Phase I/II Trial of Sapanisertib in Combination With Cabozantinib in β-catenin-mutated Hepatocellular Carcinoma (SAPHIRE)
Primary endpoint: Dose-limiting toxicities and incidence of adverse events
An Open-label, Multi-Center, Phase 2 Clinical Trial Evaluating Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel, and a Substudy Evaluating PIKTOR With Paclitaxel Plus an Insulin-Suppressing Diet, in Patients With Advanced or Recurrent Endometrial Cancer
Primary endpoint: Objective Response Rate (ORR)
Molecular Analysis for Therapy Choice (MATCH)
Primary endpoint: Objective response rate (ORR)
Frequently asked questions
Who is developing sapanisertib?
sapanisertib is being developed by Calithera Biosciences, Inc..
How many clinical trials involve sapanisertib?
BioSniper tracks 4 clinical trials involving sapanisertib.